Search the Newsreel

Harvard Bioscience, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HBIO) 2026-08-12

Harvard Bioscience, Inc. (HBIO) published its slide deck in conjunction with its Q2 2026 earnings call. The company reported an EPS of -$0.14, beating estimates by $0.07, and revenue of $22.73M, which was an 11.13% year-over-year increase and beat by $1.28M. This article provides …

Harvard Bioscience (NASDAQ: HBIO) grows Q2 sales but faces higher debt costs

Harvard Bioscience (NASDAQ: HBIO) reported an 11.1% increase in Q2 2026 revenue, reaching $22.7 million, primarily driven by strong sales to CROs in the Americas and distributors in Asia-Pacific. Despite revenue growth and ongoing cost-saving initiatives like "Project Viking," the company posted a net …

HARVARD BIOSCIENCE INC 2026: Revenue $22.73M, EPS ($0.64) — 10-Q Summary

HARVARD BIOSCIENCE INC (HBIO) reported its second-quarter 2026 results, showing an 11.1% year-over-year revenue increase to $22.73M. Despite this growth, the company recorded a net loss of ($2.91M) and a diluted loss per share of ($0.64). The revenue growth was primarily driven by increased …

Harvard Bioscience targets 3% to 5% full-year 2026 revenue growth as CMT and China mix shifts gross margin to 57% to 59%

Earnings Call Insights: Harvard Bioscience (HBIO) Q2 2026 MANAGEMENT VIEW * "That disciplined focus and execution helped us deliver strong second quarter performance, highlighted by double-digit revenue growth across our CMT and preclinical portfolios and solid operational execution that reinforced our confidence in raising …

Harvard Bioscience beats estimates, raises 2026 guidance

Harvard Bioscience Inc. (NASDAQ:HBIO) surpassed analyst expectations for its second-quarter 2026 results, reporting adjusted EPS of -$0.14 and revenue of $22.7 million, exceeding estimates. The company also raised its full-year 2026 revenue guidance to 3%-5% YoY growth, citing strong demand for its telemetry and …

Harvard Bioscience (HBIO) grows Q2 2026 sales but stays in loss

Harvard Bioscience (HBIO) reported an 11.1% increase in Q2 2026 revenue, reaching $22.7 million, with full-year revenue guidance raised to 3%-5% growth. Despite top-line expansion and improved gross margins, the company remains unprofitable, recording a Q2 2026 net loss of $2.9 million. Operating cash …

Harvard Bioscience Q2 Revenue Rises 11 Percent to $22.7 Million

Harvard Bioscience (HBIO) reported an 11% increase in Q2 2026 revenue, reaching $22.7 million, despite a GAAP net loss of $2.9 million. The company also raised its full-year 2026 revenue guidance to 3% to 5% growth. Insider trading data shows multiple purchases of HBIO …

Harvard Bioscience Lifts 2026 Revenue Outlook After 11% Q2 Growth

Harvard Bioscience (HBIO) reported an 11% year-over-year revenue increase to $22.7 million in Q2 2026, leading them to raise their full-year 2026 revenue growth guidance to 3-5%. Despite a widened GAAP net loss, adjusted EBITDA saw growth, and the company provided Q3 2026 revenue …

Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Harvard Bioscience Inc (HBIO) has an earnings forecast score of 7.00, ranking 153rd in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $2.00 with a "Buy" rating based on 2 analysts. The company's expected revenue for the next …

Harvard Bioscience Inc (HBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Harvard Bioscience Inc (HBIO), detailing its current price momentum score, support and resistance levels, and various technical indicators. It presents a summary of buy, sell, and neutral signals based on indicators like MACD, RSI, and moving averages, …

Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 ...

Harvard Bioscience, Inc. (Nasdaq: HBIO) announced it will release its financial results for the second quarter of 2026 on August 11, 2026, before market open. The company will also host a conference call at 8:00 a.m. Eastern Time on the same day to discuss …

Harvard Bioscience Q2 Results: Earnings Call Set for August 11

Harvard Bioscience Inc (NASDAQ: HBIO) will release its second-quarter 2026 financial results before market open on August 11, 2026. The company will host a conference call on the same day at 8:00 AM ET to discuss its performance and business outlook. Financial materials, including …

Harvard Bioscience to release quarter results before market opens Aug. 11

Harvard Bioscience (Nasdaq: HBIO) announced that it will release its financial results for the quarter ended June 30, 2026, before the market opens on August 11, 2026. The company will host an earnings conference call at 8:00 a.m. Eastern Time on the same day …

Harvard Bioscience Inc (HBIO) Cash Flow

This article provides access to the quarterly and annual cash flow statements for Harvard Bioscience Inc (HBIO), allowing users to evaluate the company's financial health and stability. It details various components of cash flow, such as operating, investing, and financing activities, along with year-over-year …

Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Harvard Bioscience Inc (HBIO), highlighting its current valuation score, P/E ratio, and industry ranking. The company's valuation score is 8.98, placing it 51st out of 199 in the Healthcare Equipment & Supplies industry. The article notes that …

Harvard Bioscience Inc (HBIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Harvard Bioscience Inc (HBIO), listing its major shareholders and their respective proportions. It also breaks down shareholder types, and provides institutional shareholding data over several quarters, showing changes in the number of institutions and shares held. Additionally, …

Harvard Bioscience Inc (HBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed breakdown of Harvard Bioscience Inc's (HBIO) revenue, segmented by business and geographic region. For the fiscal year 2025, the company's revenue heavily relies on instruments, equipment, software, and accessories, which constitute over 90% of its total revenue, with the …

Harvard Bioscience, Inc. Revenue Breakdown – MUN:HBI0

This article provides a revenue breakdown for Harvard Bioscience, Inc. (MUN:HBI0), highlighting its top-performing segment, "Instruments, Equipment, Software and Accessories," and the major geographical contributor, the United States. In the last year, the company generated €73.69 million, with €66.63 million from its primary segment …

HBIO|Harvard Bioscience Inc|Price:6.000|Chg%:-0.190

Harvard Bioscience Inc. (HBIO) closed at $6.00, down 3.07% on July 24th. The company, which specializes in life science technologies, is considered fairly valued with strong fundamentals and high growth potential. Analysts rate HBIO as a "Buy" with a target price of $6.00, and …

Harvard Bioscience Inc (HBIO) Institutional Confidence

Harvard Bioscience Inc (HBIO) has an institutional shareholding score of 5.00, placing it 108th in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 54.17%, showing a 13.62% increase quarter-over-quarter. James Simons is the largest institutional shareholder, holding 2.25% of outstanding shares.

Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis

Harvard Bioscience Inc (HBIO) currently holds a financial score of 7.07, ranking 113 out of 200 in the Healthcare Equipment & Supplies industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue decreased by 4.68% year-over-year to $20.75 million, …

Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO)

Harvard Bioscience (HBIO) Slips Slightly, Holding Above Support at $5.71 - Call Resistance

Metis TechBio (SEHK:7666) Valuation Under Scrutiny After Sharp Short Term Share Price Slide

Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts

METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals

Metis TechBio Co., Ltd. Announces Allotment Results and Listing Details for HKEX IPO (Stock Code: 7666)

HARVARD BIOSCIENCE ($HBIO) Releases Q1 2026 Earnings

HBIO Q1 2026 Earnings Transcript

When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)?

BRIEF: Metis TechBio launches $250 million Hong Kong IPO

Further Upside For Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Introduce Price Risks After 27% Bounce

What is the current Price Target and Forecast for Harvard Bioscience (HBIO)